Saad Usmani, MD, FACP, Levine Cancer Institute & Atrium Health, Charlotte, NC, discusses the optimal choice of therapy beyond first relapse in multiple myeloma. The BELLINI, CANDOR and ICARIA-MM trials (NCT02755597, NCT03158688, NCT02990338) are discussed, as are CAR-T cell approaches to therapy. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).